Prognostic Assessment of Three Single-Nucleotide Polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in Extrahepatic Cholangiocarcinoma

REFERENCES

• Patel, T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33, 1353.
   PubMed Web of Science ®Google Scholar
• Shaib, Y.; El-Serag, H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24, 115.
   PubMed Web of Science ®Google Scholar
• Shaib, Y.H.; Davila, J.A.; McGlynn, K.; El-Serag, H.B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 2004, 40, 472.
   PubMed Web of Science ®Google Scholar
• Okada, K.; Shimizu, Y.; Nambu, S.; Higuchi, K.; Watanabe, A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994, 9, 462.
   PubMed Web of Science ®Google Scholar
• Yokomuro, S.; Tsuji, H.; Lunz, J.G.III; Sakamoto, T.; Ezure, T.; Murase, N.; Demetris, A.J. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000, 32, 26.
   PubMed Web of Science ®Google Scholar
• Isomoto, H.; Kobayashi, S.; Werneburg, N.W.; Bronk, S.F.; Guicciardi, M.E.; Frank, D.A.; Gores, G.J. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42, 1329.
   PubMed Web of Science ®Google Scholar
• Isomoto, H.; Mott, J.L.; Kobayashi, S.; Werneburg, N.W.; Bronk, S.F.; Haan, S.; Gores, G.J. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007, 132, 384.
   PubMed Web of Science ®Google Scholar
• Kobayashi, S.; Werneburg, N.W.; Bronk, S.F.; Kaufmann, S.H.; Gores, G.J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005, 128, 2054.
   PubMed Web of Science ®Google Scholar
• Park, J.; Tadlock, L.; Gores, G.J.; Patel, T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999, 30, 1128.
   PubMed Web of Science ®Google Scholar
• Schmitz, K.J.; Lang, H.; Wohlschlaeger, J.; Sotiropoulos, G.C.; Reis, H.; Schmid, K.W.; Baba, H.A. AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 2007, 13, 6470.
   PubMed Web of Science ®Google Scholar
• Tadlock, L.; Patel, T. Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 2001, 33, 43.
   PubMed Web of Science ®Google Scholar
• Yoon, J.H.; Canbay, A.E.; Werneburg, N.W.; Lee, S.P.; Gores, G.J. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 2004, 39, 732.
   PubMed Web of Science ®Google Scholar
• Yoon, J.H.; Werneburg, N.W.; Higuchi, H.; Canbay, A.E.; Kaufmann, S.H.; Akgul, C.; Edwards, S.W.; Gores, G.J. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002, 62, 6500.
   PubMed Web of Science ®Google Scholar
• Taniai, M.; Grambihler, A.; Higuchi, H.; Werneburg, N.; Bronk, S.F.; Farrugia, D.J.; Kaufmann, S.H.; Gores, G.J. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004, 64, 3517.
   PubMed Web of Science ®Google Scholar
• Hahn, S.A.; Bartsch, D.; Schroers, A.; Galehdari, H.; Becker, M.; Ramaswamy, A.; Schwarte-Waldhoff, I.; Maschek, H.; Schmiegel, W. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998, 58, 1124.
   PubMed Web of Science ®Google Scholar
• Isa, T.; Tomita, S.; Nakachi, A.; Miyazato, H.; Shimoji, H.; Kusano, T.; Muto, Y.; Furukawa, M. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002, 49, 604.
   PubMed Web of Science ®Google Scholar
• Kang, Y.K.; Kim, W.H.; Lee, H.W.; Lee, H.K.; Kim, Y.I. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999, 79, 477.
   PubMed Web of Science ®Google Scholar
• Taniai, M.; Higuchi, H.; Burgart, L.J.; Gores, G.J. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002, 123, 1090.
   PubMed Web of Science ®Google Scholar
• Watanabe, M.; Asaka, M.; Tanaka, J.; Kurosawa, M.; Kasai, M.; Miyazaki, T. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology 1994, 107, 1147.
   PubMed Web of Science ®Google Scholar
• Melum, E.; Karlsen, T.H.; Schrumpf, E.; Bergquist, A.; Thorsby, E.; Boberg, K.M.; Lie, B.A. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008, 47, 90.
   PubMed Web of Science ®Google Scholar
• Schmitz, K.J.; Lang, H.; Frey, U.H.; Sotiropoulos, G.C.; Wohlschlaeger, J.; Reis, H.; Takeda, A.; Siffert, W.; Schmid, K.W.; Baba, H.A. GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 2007, 9, 159.
   PubMed Web of Science ®Google Scholar
• Kozasa, T.; Itoh, H.; Tsukamoto, T.; Kaziro, Y. Isolation and characterization of the human Gs alpha gene. Proc Natl Acad Sci U S A 1988, 85, 2081.
   PubMed Web of Science ®Google Scholar
• Frey, U.H.; Nuckel, H.; Sellmann, L.; Siemer, D.; Kuppers, R.; Durig, J.; Duhrsen, U.; Siffert, W. The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006, 12, 5686.
   PubMed Web of Science ®Google Scholar
• Frey, U.H.; Eisenhardt, A.; Lummen, G.; Rubben, H.; Jockel, K.H.; Schmid, K.W.; Siffert, W. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 2005, 14, 871.
   PubMed Web of Science ®Google Scholar
• Myklebust, J.H.; Josefsen, D.; Blomhoff, H.K.; Levy, F.O.; Naderi, S.; Reed, J.C.; Smeland, E.B. Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression. J Cell Physiol 1999, 180, 71.
   PubMedGoogle Scholar
• Frey, U.H.; Alakus, H.; Wohlschlaeger, J.; Schmitz, K.J.; Winde, G.; van Calker, H.G.; Jockel, K.H.; Siffert, W.; Schmid, K.W. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005, 11, 5071.
   PubMed Web of Science ®Google Scholar
• Frey, U.H.; Lummen, G.; Jager, T.; Jockel, K.H.; Schmid, K.W.; Rubben, H.; Muller, N.; Siffert, W.; Eisenhardt, A. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006, 12, 759.
   PubMed Web of Science ®Google Scholar
• Lehnerdt, G.F.; Franz, P.; Zaqoul, A.; Schmitz, K.J.; Grehl, S.; Lang, S.; Schmid, K.W.; Siffert, W.; Jahnke, K.; Frey, U.H. Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res 2008, 14, 1753.
   PubMed Web of Science ®Google Scholar
• Siffert, W.; Rosskopf, D.; Siffert, G.; Busch, S.; Moritz, A.; Erbel, R.; Sharma, A.M.; Ritz, E.; Wichmann, H.E.; Jakobs, K.H.; Horsthemke, B. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998, 18, 45.
   PubMed Web of Science ®Google Scholar
• Siffert, W.; Forster, P.; Jockel, K.H.; Mvere, D.A.; Brinkmann, B.; Naber, C.; Crookes, R.; Du, P.H.A.; Epplen, J.T.; Fridey, J.; Freedman, B.I.; Muller, N.; Stolke, D.; Sharma, A.M.; Al Moutaery, K.; Grosse-Wilde, H.; Buerbaum, B.; Ehrlich, T.; Ahmad, H.R.; Horsthemke, B.; Du Toit, E.D.; Tiilikainen, A.; Ge, J.; Wang, Y.; Rosskopf, D.; Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999, 10, 1921.
   PubMed Web of Science ®Google Scholar
• Siffert, W. Molecular genetics of G proteins and atherosclerosis risk. Basic Res Cardiol 2001, 96, 606.
   PubMed Web of Science ®Google Scholar
• Nuckel, H.; Frey, U.; Aralh, N.; Durig, J.; Duhrsen, U.; Siffert, W. The CC genotype of the C825T polymorphism of the G protein beta3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia. Leuk Lymphoma 2003, 44, 1739.
   PubMed Web of Science ®Google Scholar
• Sarrazin, C.; Berg, T.; Weich, V.; Mueller, T.; Frey, U.H.; Zeuzem, S.; Gerken, G.; Roggendorf, M.; Siffert, W. GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. J Hepatol 2005, 43, 388.
   PubMed Web of Science ®Google Scholar
• Park, B.L.; Kim, L.H.; Cheong, H.S.; Cho, H.Y.; Kim, E.M.; Shin, H.D.; Kim, Y.S.; Lee, C. Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). J Hum Genet 2004, 49, 449.
   PubMed Web of Science ®Google Scholar
• Shin, H.D.; Cheong, H.S.; Park, B.L.; Kim, L.H.; Han, C.S.; Lee, I.H.; Park, S.K. Common MCL1 polymorphisms associated with risk of tuberculosis. BMB Rep 2008, 41, 334.
   PubMed Web of Science ®Google Scholar
• Youle, R.J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9, 47.
   PubMed Web of Science ®Google Scholar
• Nuckel, H.; Frey, U.H.; Bau, M.; Sellmann, L.; Stanelle, J.; Durig, J.; Jockel, K.H.; Duhrsen, U.; Siffert, W. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007, 109, 290.
   PubMed Web of Science ®Google Scholar
• Nishio, H.; Nagino, M.; Oda, K.; Ebata, T.; Aral, T.; Nimura, Y. TNM classification for perihilar cholangiocarcinoma: comparison between 5th and 6th editions of the AJCC/UICC staging system. Langenbecks Arch Surg 2005, 390, 319.
   PubMed Web of Science ®Google Scholar
• Otterbach, F.; Callies, R.; Frey, U.H.; Schmitz, K.J.; Wreczycki, C.; Kimmig, R.; Siffert, W.; Schmid, K.W. The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat 2007, 105, 311.
   PubMed Web of Science ®Google Scholar
• Bachmann, H.S.; Otterbach, F.; Callies, R.; Nuckel, H.; Bau, M.; Schmid, K.W.; Siffert, W.; Kimmig, R. The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res 2007, 13, 5790.
   PubMed Web of Science ®Google Scholar
• Buck, E.; Iyengar, R. Modular design of Gbeta as the basis for reversible specificity in effector stimulation. J Biol Chem 2001, 276, 36014.
   PubMed Web of Science ®Google Scholar
• Harry, A.; Chen, Y.; Magnusson, R.; Lyengar, R.; Weng, G. Differential regulation of adenylyl cyclases by Galphas. J Biol Chem 1997, 272, 19017.
   PubMed Web of Science ®Google Scholar
• Keiper, M.; Stope, M.B.; Szatkowski, D.; Bohm, A.; Tysack, K.; Vom Dorp, F.; Saur, O.; Oude Weernink, P.A.; Evellin, S.; Jakobs, K.H.; Schmidt, M. Epac- and Ca2+ -controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. J Biol Chem 2004, 279, 46497.
   PubMed Web of Science ®Google Scholar
• Kiermayer, S.; Biondi, R.M.; Imig, J.; Plotz, G.; Haupenthal, J.; Zeuzem, S.; Piiper, A. Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells. Mol Biol Cell 2005, 16, 5639.
   PubMed Web of Science ®Google Scholar
• Peyssonnaux, C.; Eychene, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93, 53.
   PubMed Web of Science ®Google Scholar
• Green, D.R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305, 626.
   PubMed Web of Science ®Google Scholar